Microplasmin looks promising for the treatment of vitreomacular traction
ThromboGenics, a biotechnology company focused on vascular diseases, has completed patient enrolment for a Phase IIa trial designed to evaluate the safety and efficacy of microplasmin for the treatment of vitreomacular traction, including macular holes.
ThromboGenics, a biotechnology company focused on vascular diseases, has completed patient enrolment for a Phase IIa trial designed to evaluate the safety and efficacy of microplasmin for the treatment of vitreomacular traction, including macular holes.
The MIVI IIT trial is a Phase IIa, sham injection controlled, dose ascending (75, 125 µg) trial, which has recruited 30 patients in Europe. While the study remains masked, preliminary data demonstrates that microplasmin was well tolerated in both treatment groups and furthermore, posterior vitreous detachment (PVD) was seen in a number of patients and in some cases led to the non-surgical resolution of traction.
Unmasked results of the study will be presented later this year at the American Society of Retina Specialists annual meeting in California, US.
Newsletter
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.
